title: Human Cytomegalovirus Requires Epidermal Growth Factor Receptor Signaling To Enter and Initiate the Early Steps in the Establishment of Latency in CD34+Human Progenitor Cells.
abstract: The establishment of human cytomegalovirus (HCMV) latency and persistence relies on the successful infection of hematopoietic cells, which serve as sites of viral persistence and contribute to viral spread. Here, using blocking antibodies and pharmacological inhibitors, we document that HCMV activation of the epidermal growth factor receptor (EGFR) and downstream phosphatidylinositol 3-kinase (PI3K) mediates viral entry into CD34+human progenitor cells (HPCs), resulting in distinct cellular trafficking and nuclear translocation of the virus compared to that in other immune cells, such as we have documented in monocytes. We argue that the EGFR allows HCMV to regulate the cellular functions of these replication-restricted cells via its signaling activity following viral binding. In addition to regulating HCMV entry/trafficking, EGFR signaling may also shape the early steps required for the successful establishment of viral latency in CD34+cells, as pharmacological inhibition of EGFR increases the transcription of lytic IE1/IE2 mRNA while curbing the expression of latency-associated UL138 mRNA. EGFR signaling following infection of CD34+HPCs may also contribute to changes in hematopoietic potential, as treatment with the EGFR kinase (EGFRK) inhibitor AG1478 alters the expression of the cellular hematopoietic cytokine interleukin 12 (IL-12) in HCMV-infected cells but not in mock-infected cells. These findings, along with our previous work with monocytes, suggest that EGFR likely serves as an important determinant of HCMV tropism for select subsets of hematopoietic cells. Moreover, our new data suggest that EGFR is a key receptor for efficient viral entry and that the ensuing signaling regulates important early events required for successful infection of CD34+HPCs by HCMV.IMPORTANCEHCMV establishes lifelong persistence within the majority of the human population without causing overt pathogenesis in healthy individuals. Despite this, reactivation of HCMV from its latent reservoir in the bone marrow causes significant morbidity and mortality in immunologically compromised individuals, such as bone marrow and solid organ transplant patients. Lifelong persistent infection has also been linked with the development of various cardiovascular diseases in otherwise healthy individuals. Current HCMV therapeutics target lytic replication, but not the latent viral reservoir; thus, an understanding of the molecular basis for viral latency and persistence is paramount to controlling or eliminating HCMV infection. Here, we show that the viral signalosome activated by HCMV binding to its entry receptor, EGFR, in CD34+HPCs initiates early events necessary for successful latent infection of this cell type. EGFR and associated signaling players may therefore represent promising targets for mitigating HCMV persistence.
authors.affiliation: Department of Microbiology and Immunology, Center for Molecular and Tumor Virology, Center for Cardiovascular Diseases and Sciences, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
authors.forename: Jung Heon
authors.initials: JH
authors.lastname: Kim
authors.affiliation: Department of Microbiology and Immunology, Center for Molecular and Tumor Virology, Center for Cardiovascular Diseases and Sciences, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
authors.forename: Donna
authors.initials: D
authors.lastname: Collins-McMillen
authors.affiliation: BIO5 Institute, University of Arizona, Tucson, Arizona, USA.
authors.forename: Jason C
authors.initials: JC
authors.lastname: Buehler
authors.affiliation: BIO5 Institute, University of Arizona, Tucson, Arizona, USA.|Department of Cellular and Molecular Medicine, Department of Immunobiology, Department of Molecular and Cellular Biology, University of Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA.
authors.forename: Felicia D
authors.initials: FD
authors.lastname: Goodrum
authors.affiliation: Department of Microbiology and Immunology, Center for Molecular and Tumor Virology, Center for Cardiovascular Diseases and Sciences, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA ayuroc@lsuhsc.edu.|Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.|Center of Excellence in Arthritis and Rheumatology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Yurochko
mesh_terms: D018952:Antigens, CD34 / Q000378:metabolism; D002478:Cells, Cultured; D003587:Cytomegalovirus / Q000502:physiology*; D066246:ErbB Receptors / Q000378:metabolism*; D015967:Gene Expression Regulation, Viral; D006410:Hematopoiesis; D006412:Hematopoietic Stem Cells / Q000821:virology*; D054884:Host-Pathogen Interactions; D006801:Humans; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D015398:Signal Transduction; D053586:Virus Internalization; D017735:Virus Latency
chemical_list: D018952:Antigens, CD34; D019869:Phosphatidylinositol 3-Kinases; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: CD34+ HPC; EGFR; HCMV; latency; virus entry